MGX
Metagenomi, Inc. Common StockHealthcare·Biotechnology
$1.36
$51M market cap
Revenue
$5.2M
Free Cash Flow
$-44.8M
Rev Growth
+0.0%
FCF Margin
-869.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new
2-Year Price History
$1.35-77.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 1.3 | -23.1 | -24.6 | -23.1 | -21.2 | -21.2 | -0.0 | 140.2 | 39.2 | 37.6 | -142.2% | -- | -- |
| Act | 2025-Q4 | 3.9 | -23.1 | -24.4 | -22.5 | -23.6 | -23.6 | -0.1 | 160.8 | 40.7 | 37.6 | -105.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.36
Market Cap$51M
Enterprise Value$-50M
P/S Ratio9.9x
P/FCF--
EV/FCF--
FCF Margin (TTM)-869.0%
FCF Yield-87.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$5.2M
Net Income$-45.6M
Free Cash Flow$-44.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin-893.9%
Net Margin-883.6%
FCF Margin-869.0%
CapEx % of Revenue2.1%
SBC % of Revenue52.2%
ROIC-124.0%
WC Change % Rev23.5%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.8M
Days to Cover9.9
Change (vs Prior)-4.4%
Need at least 2 settlement dates for chart
Employees
Headcount202
Revenue / Employee$25,540
Gross Profit / Employee$19,104
Cash Runway
37.5months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
11.6%(-3.4% YoY)
36 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
5.6%(-6.7% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.1% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.4M | $1.34 | +$1.4M | +$1.4M | — | $4.04T |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | $1.72 | +$214K | +$922K | +1.2% | $63.91B |
| Catalio Capital Management, LP | $709K | $3.61 | +$0 | +$0 | +3.3% | $479M |
| Peapod Lane Capital LLC | $683K | $2.89 | +$26K | +$217K | -0.7% | $122M |
| TWO SIGMA INVESTMENTS, LP | $666K | $2.24 | +$74K | +$587K | -0.9% | $117.03B |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $530K | $1.93 | +$0 | +$398K | -2.3% | $4.93B |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $512K | $1.75 | +$466K | +$423K | +0.4% | $23.79B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $480K | $3.86 | +$70K | −$350K | +2.3% | $1.61T |
| PURA VIDA INVESTMENTS, LLC | $354K | $5.12 | +$0 | +$0 | -11.7% | $14.9M |
| BlackRock, Inc.Passive | $308K | $3.05 | +$8K | −$1.8M | -0.2% | $5.69T |
| WELLS FARGO & COMPANY/MN | $271K | $2.97 | +$112K | +$124K | -0.2% | $497.71B |
| VANGUARD FIDUCIARY TRUST COPassive | $228K | $1.34 | +$228K | +$228K | — | $395.83B |
| MILLENNIUM MANAGEMENT LLC | $228K | $7.08 | −$87K | −$20K | -0.5% | $127.40B |
| JANE STREET GROUP, LLCMM | $203K | $1.88 | −$378K | +$203K | -0.1% | $92.10B |
| STATE STREET CORPPassive | $161K | $3.09 | +$0 | −$598K | -0.2% | $2.89T |
| Resolute Advisors LLC | $121K | $4.47 | +$0 | +$0 | -7.6% | $242M |
| Man Group plc | $105K | $2.05 | +$30K | +$105K | -0.4% | $47.62B |
| NORTHERN TRUST CORPPassive | $101K | $3.33 | +$0 | −$192K | -0.2% | $755.34B |
| RBF Capital, LLC | $86K | $1.48 | +$0 | +$86K | +0.1% | $2.03B |
| BBR PARTNERS, LLC | $72K | $3.61 | +$0 | +$0 | -0.4% | $1.79B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.71%
avg per quarter
Holders (ex-self)
-0.66%
excl. this stock
Buyers (this Q)
+0.31%
9 buyers · $0.00B in
Sellers (this Q)
-0.32%
15 sellers · $0.00B out
alpha coverage: 81% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+3.3%
how holders react when this stock falls
On quiet Qs
-18.6%
−10% to +10% baseline
On rallies (+10%+)
+10.5%
how they react when this stock rises
Holders' portfolio flow this Q
+6.9%
inflows — adds are organic
Sellers' portfolio flow this Q
+5.5%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-5.6%
Holder mid (any stock)
-7.5%
Holder rally (any stock)
-10.9%
Biggest decreases this quarter
JANE STREET GROUP, LLC−$378Kα-0.1CITADEL ADVISORS LLC−$216Kα-0.4ACADIAN ASSET MANAGEMENT LLCexited−$105KMILLENNIUM MANAGEMENT LLC−$87Kα-0.5MARSHALL WACE, LLP−$69Kα+0.6Quadrature Capital Ltdexited−$55KPANAGORA ASSET MANAGEMENT INCexited−$53KMORGAN STANLEY−$43Kα-0.3XTX Topco Ltd−$38Kα-1.9Dynamic Technology Lab Private Ltdexited−$38K
New buyers this quarter
Top-5 holders · 52.4%
VANGUARD CAPITAL MANAGEMENT LLC--
RENAISSANCE TECHNOLOGIES LLC--
Catalio Capital Management, LP--
Peapod Lane Capital LLC--
TWO SIGMA INVESTMENTS, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.—Novo Holdings A/S—FARALLON CAPITAL MANAGEMENT LLC—Partner Fund Management, L.P.—HHLR ADVISORS, LTD.—MILLENNIUM MANAGEMENT LLC170KCITADEL ADVISORS LLC17KEVENTIDE ASSET MANAGEMENT, LLC—Sozo Ventures GP II, L.P.—Deep Track Capital, LP—
Analyst Coverage
Analyst Coverage
Analyst Ratings
4
1
Buy: 4Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$72K
16 txns · 5 insiders · 41,144 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-05 | SELL | Irish Jian | director, officer: Chief Executive Officer | 1,607 | $1.60 | $3K | $534K |
| 2026-03-05 | SELL | Wapnick Pamela | officer: Chief Financial Officer | 1,581 | $1.60 | $3K | $300K |
| 2026-03-05 | SELL | Wein Matthew | officer: See Remarks | 482 | $1.60 | $771 | $183K |
| 2025-12-05 | SELL | Irish Jian | director, officer: Chief Executive Officer | 1,602 | $1.77 | $3K | $999K |
| 2025-12-05 | SELL | Thomas Brian C. | director | 3,830 | $1.77 | $7K | $4.45M |
| 2025-12-05 | SELL | Wapnick Pamela | officer: Chief Financial Officer | 1,576 | $1.77 | $3K | $335K |
| 2025-12-05 | SELL | Wein Matthew | officer: See Remarks | 199 | $1.77 | $353 | $204K |
| 2025-09-05 | SELL | Irish Jian | director, officer: Chief Executive Officer | 1,602 | $1.81 | $3K | $574K |
| 2025-09-05 | SELL | Thomas Brian C. | director | 2,701 | $1.81 | $5K | $4.55M |
| 2025-09-05 | SELL | Wapnick Pamela | officer: Chief Financial Officer | 1,576 | $1.81 | $3K | $128K |
| 2025-09-05 | SELL | Wein Matthew | officer: See Remarks | 199 | $1.81 | $360 | $35K |
| 2025-06-06 | SELL | Irish Jian | director, officer: See Remarks | 6,390 | $1.75 | $11K | $552K |
| 2025-06-06 | SELL | Noonberg Sarah B. | officer: Chief Medical Officer | 5,239 | $1.75 | $9K | $191K |
| 2025-06-06 | SELL | Thomas Brian C. | director, officer: Chief Executive Officer | 10,785 | $1.75 | $19K | $4.41M |
| 2025-06-06 | SELL | Wapnick Pamela | officer: Chief Financial Officer | 1,576 | $1.75 | $3K | $126K |
| 2025-06-06 | SELL | Wein Matthew | officer: See Remarks | 199 | $1.75 | $348 | $29K |
Order Flow (FINRA, ~3w lag)
56.4%retail-2.5pp
7.8%dark+2.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Metagenomi Therapeutics: IPO Fraud Allegations and Partnership Implosions Masked by 'Therapeutic' Rebranding
Overall Risk
8/10
Fraud
7/10
Dilution
7/10
Insolvency
6/10
Earnings Overstated
4/10
Hidden Liabilities
5/10
Legal
8/10
Audit Warnings
3/10
Hidden Upside
4/10
Contextually Acceptable
3/10